Medtronic PLC (MDT)

NYSE
Currency in USD
82.60
-0.10(-0.12%)
Closed·
Pre Market
82.84+0.24(+0.29%)
·
MDT Scorecard
Full Analysis
Management has been aggressively buying back shares
Fair Value
Day's Range
82.1283.32
52 wk Range
75.9696.25
Key Statistics
Edit
Prev. Close
82.7
Open
82.51
Day's Range
82.12-83.32
52 wk Range
75.96-96.25
Volume
5.94M
Average Volume (3m)
7.73M
1-Year Change
3.93%
Book Value / Share
38.51
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
MDT Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
96.83
Upside
+17.23%
Members' Sentiments
Bearish
Bullish
ProTips
Has raised its dividend for 11 consecutive years
Show more

Medtronic Company Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. The segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists; and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat other non-exclusive diseases and conditions; and patient monitoring and airway management products. The Diabetes Operating Unit segment provides insulin pumps and consumables, continuous glucose monitoring systems, and InPen, a smart insulin pen system. The company was founded in 1949 and is headquartered in Galway, Ireland.

Medtronic PLC SWOT Analysis


Growth Challenges
Medtronic faces hurdles in meeting sales growth expectations despite its strong position in the U.S. Medical Supplies & Devices industry
Financial Resilience
Explore Medtronic's ability to beat EPS and margin expectations while maintaining a 48-year streak of consecutive dividend payments
Innovation Pipeline
Delve into Medtronic's robust product lineup, particularly in Diabetes and Cardiac Ablation, driving future growth prospects
Market Valuation
Analysts set price targets ranging from $85 to $112, with potential for re-rating as the company navigates foreign exchange challenges
Read full SWOT analysis

Medtronic PLC Earnings Call Summary for Q1/2025

  • Q1 FY2025: Revenue up 5.3%, adjusted EPS up 3% (8% constant currency). Full-year guidance raised to 4.5-5% organic revenue growth.
  • Key growth drivers: Cardiac Rhythm Management, Micro leadless pacemaker. Surgical segment growth moderate due to market factors.
  • Global partnership with Abbott for integrated CGM solutions. Gary Corona appointed Interim CFO, succeeding Karen Parkhill.
  • Focus on tuck-in M&A, share repurchases. Expects improved operating margins in H2. Committed to Hugo surgical robot as midterm growth driver.
  • Optimistic about pulsed field ablation and renal denervation growth. Q2 earnings call scheduled for November 19.
Last Updated: 20/08/2024, 22:48
Read Full Transcript

Compare MDT to Peers and Sector

Metrics to compare
MDT
Peers
Sector
Relationship
P/E Ratio
24.9x8.1x−0.5x
PEG Ratio
6.520.000.00
Price/Book
2.1x1.7x2.6x
Price / LTM Sales
3.2x0.9x2.9x
Upside (Analyst Target)
15.0%36.8%66.3%
Fair Value Upside
Unlock23.1%10.2%Unlock

Analyst Ratings

16 Buy
14 Hold
2 Sell
Ratings:
32 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 96.83
(+17.23% Upside)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 3.29%
Dividend Yield
3.39%
Industry Median 0.71%
Annualised payout
2.80
Paid quarterly
5-Years Growth
+5.65%
Growth Streak

Earnings

Latest Release
Feb 18, 2025
EPS / Forecast
1.39 / 1.36
Revenue / Forecast
8.29B / 8.33B
EPS Revisions
Last 90 days

People Also Watch

219.00
LOW
+2.14%
285.59
CB
+0.18%
462.88
SPGI
-0.24%
95.50
CL
+2.15%
58.16
MO
+1.55%

FAQ

What Is the Medtronic (MDT) Stock Price Today?

The Medtronic stock price today is 82.60

What Stock Exchange Does Medtronic Trade On?

Medtronic is listed and trades on the NYSE stock exchange.

What Is the Stock Symbol for Medtronic?

The stock symbol for Medtronic is "MDT."

Does Medtronic Pay Dividends? What’s The Current Dividend Yield?

The Medtronic dividend yield is 3.39%.

What Is the Medtronic Market Cap?

As of today, Medtronic market cap is 105.94B.

What is Medtronic Earnings Per Share?

The Medtronic EPS is 3.29.

What Is the Next Medtronic Earnings Date?

Medtronic will release its next earnings report on 20 May 2025.

From a Technical Analysis Perspective, Is MDT a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.